share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股SEC公告 ·  2024/06/28 04:44

Moomoo AI 已提取核心訊息

Illumina announced it will recognize significant impairment charges in the second quarter of 2024 following an impairment test of GRAIL-related assets. The company estimates a goodwill impairment charge of $1,466 million, representing the full remaining carrying value of GRAIL's goodwill as of March 31, 2024.Additionally, Illumina will record a $420 million impairment charge for GRAIL's in-process research and development (IPR&D) intangible asset. The company stated these charges will be excluded from non-GAAP financial metrics and are not expected to result in any material future cash expenditures.
Illumina announced it will recognize significant impairment charges in the second quarter of 2024 following an impairment test of GRAIL-related assets. The company estimates a goodwill impairment charge of $1,466 million, representing the full remaining carrying value of GRAIL's goodwill as of March 31, 2024.Additionally, Illumina will record a $420 million impairment charge for GRAIL's in-process research and development (IPR&D) intangible asset. The company stated these charges will be excluded from non-GAAP financial metrics and are not expected to result in any material future cash expenditures.
總部位於加利福尼亞州聖迭戈的生物技術公司illumina,於2024年6月27日向美國證券交易委員會提交了一份修改後的8-K/A表格。報告提供了關於先前宣佈的特定業務活動分拆的財務影響的更新。illumina已經完成了減值測試,並估計爲2024年第二季度計提了1,466億美元的商譽減值費用,這代表了與其GRAIL業務相關的商譽的全部剩餘賬面價值,截至2024年3月31日。此外,公司預計在GRAIL的在研研發(IPR&D)無形資產上計提4.2億美元的減值損失。這些費用預計不會導致任何重大的未來現金支出,並將從illumina的非GAAP財務指標中排除。
總部位於加利福尼亞州聖迭戈的生物技術公司illumina,於2024年6月27日向美國證券交易委員會提交了一份修改後的8-K/A表格。報告提供了關於先前宣佈的特定業務活動分拆的財務影響的更新。illumina已經完成了減值測試,並估計爲2024年第二季度計提了1,466億美元的商譽減值費用,這代表了與其GRAIL業務相關的商譽的全部剩餘賬面價值,截至2024年3月31日。此外,公司預計在GRAIL的在研研發(IPR&D)無形資產上計提4.2億美元的減值損失。這些費用預計不會導致任何重大的未來現金支出,並將從illumina的非GAAP財務指標中排除。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息